The FDA had been investigating the occurrence of nitrosodimethylamine (NDMA) in certain blood pressure and heart failure medicine. NDMA has been classified as a probable human cancer – causing ingredient. After recognizing NDMA impurities in these products, the FDA released a statement mid-September announcing that Zantac in its generic form, ranitidine, may contain low levels of NDMA. Now that NDMA has been discovered in certain batches of Zantac drugs, the FDA has recommended several recalls.
If you, or anyone you know, have purchased Zantac or the generic form, ranitidine, please contact Finkelstein Thompson LLP. You can reach us at contact@finkelsteinthompson.com or call us toll-free at 1-844-280-5009.
